Epstein Secrets

— raise questions of whether the Republican strategy of voter restrictions served the party's interests as it once did." However, The Hill (11/14, Polus, 2.98M) reports that Fox Business host Lou Dobbs, "a vocal Trump supporter," on Friday "vehemently defended...Trump's claims that he isn't receiving

g maker to release an early analysis of vaccine trial data," could apply for the FDA's emergency authorization "as early as this week." BioNTech CEO Ugur Sahin: "If everything continues to go well, we will start to deliver the vaccine end of this year, beginning next year." However, Lopez added, "Supplying

— raise questions of whether the Republican strategy of voter restrictions served the party's interests as it once did." However, The Hill (11/14, Polus, 2.98M) reports that Fox Business host Lou Dobbs, "a vocal Trump supporter," on Friday "vehemently defended...Trump's claims that he isn't receiving

g maker to release an early analysis of vaccine trial data," could apply for the FDA's emergency authorization "as early as this week." BioNTech CEO Ugur Sahin: "If everything continues to go well, we will start to deliver the vaccine end of this year, beginning next year." However, Lopez added, "Supplying

- raise questions of whether the Republican strategy of voter restrictions served the party's interests as it once did." However, The Hill (11/14, Polus, 2.98M) reports that Fox Business host Lou Dobbs, "a vocal Trump supporter," on Friday "vehemently defended...Trump's claims that he isn't receiving

g maker to release an early analysis of vaccine trial data," could apply for the FDA's emergency authorization "as early as this week." BioNTech CEO Ugur Sahin: "If everything continues to go well, we will start to deliver the vaccine end of this year, beginning next year." However, Lopez added, "Supplying